Studies involving Collaborative Cross 8 founders          

Filter by:
Data set Procedure What's in this data set Panel Sex Age (weeks) Year
Auwerx2 body weight
with high-fat diet 		inbred w/CC8 both 8-21 wks 2021
Auwerx2 glucose tolerance
with high-fat diet 		Plasma glucose levels: 0, 15, 30, 45, 60, 90, 120, 150, and 180 min, post oral gavage following overnight fast. inbred w/CC8 both 8-21 wks 2021
Auwerx2 hormone quantification
with high-fat diet 		Insulin levels following glucose post oral gavage: 0, 15, 30 min. inbred w/CC8 both 8-21 wks 2021
Auwerx2 intake monitoring
with high-fat diet 		Food intake. inbred w/CC8 both 8-21 wks 2021
Auwerx2 lipid profile
with high-fat diet 		Cholesterol, HDL, LDL, triglycerides, free fatty acids. inbred w/CC8 both 8-21 wks 2021
Auwerx2 metabolic panel
with high-fat diet 		Enzymes, creatinine, iron, lactate, urea. inbred w/CC8 both 8-21 wks 2021
Auwerx2 monitoring system
with high-fat diet 		Oxygen consumption, carbon dioxide production, respiratory exchange rate (RER); activity. inbred w/CC8 both 8-21 wks 2021
Auwerx2 organ dimensions
with high-fat diet 		Intestine length. inbred w/CC8 both 8-21 wks 2021
Auwerx2 organ weights
with high-fat diet 		Cecum, muscles, heart, heart-atria, kidney, liver, spleen, fat pads. inbred w/CC8 both 8-21 wks 2021
Auwerx2 treadmill endurance test
with high-fat diet 		Distance traveled. inbred w/CC8 both 8-21 wks 2021
Benavides1 genotype assessment Gpr84 allele assessment. PCR, sequencing. inbred w/CC8   (58) both 6wks 2013
Bubier3 monitoring system
with morphine 		Induced respiratory depression, time to recovery (for mice that survived), survival data (for mice that did not survive). inbred w/CC8   (8) both 8-24wks 2020
CGDpheno1 body size and weight Body weight and length. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 complete blood count Hematology. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 DXA Body mass, fat mass, lean mass, bone mineral density. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 lipid profile Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 metabolic panel Clinical blood chemistry (plasma). 4h fast. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno3 body weight Body weight CC diallel w/par   (62) both 8-16wks 2012
CGDpheno3 complete blood count Hematology. CC diallel w/par   (62) both 8-16wks 2012
CGDpheno3 DXA Body mass, fat mass, lean mass, bone mineral density and content, bone area. CC diallel w/par   (62) both 8-16wks 2012
CGDpheno3 ECG Wave amplitudes and intervals. Conscious. CC diallel w/par   (62) both 8-16wks 2012
CGDpheno3 lipid profile Cholesterol, HDL, triglycerides. 4h fast, plasma. CC diallel w/par   (62) both 8-16wks 2012
CGDpheno3 metabolic panel Glucose (plasma). 4h fast. CC diallel w/par   (62) both 8-16wks 2012
CGDpheno3 tail cuff Heart rate and blood pressure. Conscious mice. CC diallel w/par   (62) both 8-16wks 2012
Chesler2 behavior observation Wildness scoring. CC diallel w/par   (62) both 7-15wks 2011
Chesler2 body size and weight Body weight, body length, tail length. CC diallel w/par   (62) both 7-15wks 2011
Chesler2 colony observation Reproduction, fecundity. CC diallel w/par   (62) both 7-15wks 2011
Chesler2 complete blood count Hematology. CC diallel w/par   (62) both 7-15wks 2011
Chesler2 fat pad weights Gonadal fat pad weight. CC diallel w/par   (62) both 7-15wks 2011
Chesler2 light-dark box Anxiety, avoidance behavior. 10 min test. CC diallel w/par   (62) both 7-15wks 2011
Chesler2 metabolic panel Clinical blood chemistry. 16h fast. CC diallel w/par   (62) both 7-15wks 2011
Chesler2 monitoring system Sleep patterns. Dark period, total, peak activity. Baseline and after sleep deprivation. CC diallel w/par   (62) both 7-15wks 2011
Chesler2 nociception assay Hot plate and pressure on tail. CC diallel w/par   (62) both 7-15wks 2011
Chesler2 open field test Locomotor activity, exploratory, anxiety-related behavior. 10 min test. CC diallel w/par   (62) both 7-15wks 2011
Chesler2 organ weights Heart, kidney weights. CC diallel w/par   (62) both 7-15wks 2011
Chesler3 behavior observation Wildness scoring. CC pre w/par   (367) both 7-15wks 2011
Chesler3 body size and weight Body weight, tail length. CC pre w/par   (367) both 7-15wks 2011
Chesler3 bone dimensions Femur. CC pre w/par   (367) both 7-15wks 2011
Chesler3 colony observation Reproduction, fecundity. CC pre w/par   (367) both 7-15wks 2011
Chesler3 complete blood count Hematology. CC pre w/par   (367) both 7-15wks 2011
Chesler3 fat pad weights Gonadal fat pad weights. CC pre w/par   (367) both 7-15wks 2011
Chesler3 light-dark box Anxiety, avoidance behavior. 10 min test. CC pre w/par   (367) both 7-15wks 2011
Chesler3 metabolic panel Clinical blood chemistry. 16h fast. CC pre w/par   (367) both 7-15wks 2011
Chesler3 monitoring system Sleep patterns. Dark period, total, peak activity. Baseline and after sleep deprivation. CC pre w/par   (367) both 7-15wks 2011
Chesler3 nociception assay Hot plate and pressure on tail. CC pre w/par   (367) both 7-15wks 2011
Chesler3 open field test Locomotor activity, exploratory, anxiety-related behavior. 10 min test. CC pre w/par   (367) both 7-15wks 2011
Chesler3 organ dimensions Kidney length and volume. CC pre w/par   (367) both 7-15wks 2011
Chesler3 organ weights Heart, brain, kidney, spleen, gonadal fat pads, testicle weights. CC pre w/par   (367) both 7-15wks 2011
Chesler4 body weight Body weight DO population w/par   (9) both 12-16wks 2013
Chesler4 light-dark box Anxiety, avoidance behavior. 20 min test. DO population w/par   (9) both 12-16wks 2013
Chesler4 nociception assay Hot plate. DO population w/par   (9) both 12-16wks 2013
Chesler4 open field test Locomotor activity, exploratory, anxiety-related behavior. 20 min test. DO population w/par   (9) both 12-16wks 2013
Chesler4 tail suspension test Frequency climbing, time immobile, latency immobile. 5 min test. DO population w/par   (9) both 12-16wks 2013
Chesler4 visual cliff Anxiety, avoidance behavior. 20 min test. DO population w/par   (9) both 12-16wks 2013
Collins1 complete blood count Hematology. CC pre w/par   (139) m 10-14wks 2012
Crowley1 behavior observation
with haloperidol 		Observed involuntary repetitive movement. Baseline vs. during and after haloperidol 60d implant (several timepoints). inbred w/CC8   (27) m 9-28wks 2012
Crowley1 body weight
with haloperidol 		Baseline vs. after haloperidol 60d implant. inbred w/CC8   (27) m 9-28wks 2012
Crowley1 drug and metabolite quantification
with haloperidol 		Haloperidol concentration (plasma). Baseline vs. during and after haloperidol 60d implant (several timepoints). inbred w/CC8   (27) m 9-28wks 2012
Crowley1 inclined screen test
with haloperidol 		Baseline vs. during and after haloperidol 60d implant (several timepoints). inbred w/CC8   (27) m 9-28wks 2012
Crowley1 open field test
with haloperidol 		Locomotor activity, exploratory behavior, involuntary movement. Baseline vs. haloperidol 60d implant (several timepoints). 60 min test. inbred w/CC8   (27) m 9-28wks 2012
CSNA02 bottle choice test Palatable food consumption, preference for Boost solution. CC w/par   (18) both 10-39wks 2023
CSNA02 open field test Locomotor response to novelty, habituation. CC w/par   (18) both 10-39wks 2023
CSNA02 operant conditioning chamber Reversal learning (impulsive action) and delay discounting (impulsive choice). CC w/par   (18) both 10-39wks 2023
CSNA03 conditioned place preference test In novel zone: exploration counts, entrance counts, time spent, activity counts, movement counts. CC w/CC8   (61) both 4-25wks 2021
CSNA03 hole board test Number of entries, novel entries, and repeat entries. CC w/CC8   (61) both 4-25wks 2021
CSNA03 in vitro assay Circadian parameters in fibroblast cultures: period, amplitude, phase, damping rate, goodness of fit. CC w/CC8   (61) both 4-25wks 2021
CSNA03 light-dark box Distance traveled, ambulatory time and counts, resting time, stereotypic time and counts, jumping time and counts, vertical time and counts, time in light/dark. CC w/CC8   (61) both 4-25wks 2021
CSNA03 open field test
with cocaine 		Distance traveled, habituation ratio, number of rears, ambulatory time, time in perimeter, corners, and center; cocaine sensitization. CC w/CC8   (61) both 4-25wks 2021
CSNA03 operant conditioning chamber
with cocaine 		Number of infusions, active lever presses, inactive lever presses, intravenous self administration, reversal learning. CC w/CC8   (61) both 4-25wks 2021
DiPetrillo2 urinalysis Microalbumin, creatinine, ratio. CC pre w/par   (163) m 10wks 2012
Ferris1 body weight
with influenza A (H1N1) virus 		Body weight CC pre w/par   (163) f 8-16wks 2012
Ferris1 health assessment
with influenza A (H1N1) virus 		Clinical health assessment score and strain susceptibility index 4 days after infection with influenza A (H1N1) virus. CC pre w/par   (163) f 8-16wks 2012
Ferris1 histopathology
with influenza A (H1N1) virus 		Lungs and airway 4 days after infection with influenza A (H1N1) virus. CC pre w/par   (163) f 8-16wks 2012
Ferris1 in vitro assay
with influenza A (H1N1) virus 		Viral replication log titer 4 days after infection with influenza A (H1N1) virus. In vitro. CC pre w/par   (163) f 8-16wks 2012
GMC01 open field test Locomotor, exploratory, and anxiety-related behavior. 20 min test some at 5 min intervals. inbred w/CC8   (8) both 8-9wks 2020
GMC02 grip strength Several trials. inbred w/CC8   (8) both 8-10wks 2020
GMC03 observation (SHIRPA) Behavior, and neurosensory responses (SHIRPA protocol). inbred w/CC8   (8) both 8-10wks 2020
GMC05 acoustic startle test Acoustic startle response, prepulse inhibition. inbred w/CC8   (8) both 9-10wks 2020
GMC07 nociception assay Hot plate (two trials). inbred w/CC8   (8) both 11-12wks 2020
GMC08 transepidermal water loss test Transepidermal water loss in condenser chamber. inbred w/CC8   (8) both 11-12wks 2020
GMC09 intake monitoring Food, water intake. 21h test. inbred w/CC8   (8) both 12-13wks 2020
GMC09 monitoring system Locomotor activity and energy metabolism. 21h test. inbred w/CC8   (8) both 12-13wks 2020
GMC10 NMR Body mass, fat and lean tissue mass. inbred w/CC8   (8) both 12-13, 18-19wks 2020
GMC11 glucose tolerance 0 to 120 min after 20% glucose i.p., 16h fast. inbred w/CC8   (6) both 13-14wks 2020
GMC12 echocardiography Cardiovascular function and morphology. inbred w/CC8   (8) both 14-15wks 2020
GMC14 computed tomography Retinal thickness and fundus vessels. inbred w/CC8   (8) both 14-17wks 2020
GMC14 organ dimensions Axial length of eye. inbred w/CC8   (8) both 14-17wks 2020
GMC14 Scheimpflug imaging Eye lens density. inbred w/CC8   (8) both 14-17wks 2020
GMC14 virtual optomotor Threshold of spatial frequency. inbred w/CC8   (8) both 14-17wks 2020
GMC15 complete blood count Hematology. inbred w/CC8   (8) both 20-21wks 2020
GMC16 lipid profile Cholesterol, triglycerides. No fast, plasma. inbred w/CC8   (8) both 16-17, 20-21wks 2020
GMC16 metabolic panel Clinical blood chemistry (plasma). No fast. inbred w/CC8   (8) both 16-17, 20-21wks 2020
GMC18 body size and weight Body weight and length. inbred w/CC8   (8) both 17-18wks 2020
GMC18 DXA Body mass, fat mass, lean mass, bone mineral density and content, bone area. inbred w/CC8   (8) both 17-18wks 2020
GMC18 X-ray Lumbar vertebrae count. inbred w/CC8   (8) both 17-18wks 2020
GMC19 ventilator Lung, respiratory function. inbred w/CC8   (8) f 21-22wks 2020
GMC20 autoantibody quantification Anti-DNA autoantibodies, rheumatoid factor. inbred w/CC8   (8) both 16-17, 20-21wks 2020
GMC20 immunoglobulin quantification Immunoglobulins (plasma). inbred w/CC8   (8) both 16-17, 20-21wks 2020
GMC21 bone dimensions Tibia bone length. inbred w/CC8   (8) both 20-21wks 2020
GMC21 organ weights Heart, liver, spleen weights. inbred w/CC8   (8) both 20-21wks 2020
GMC22 body weight Body weight and growth curve from 8wks to 21wks. inbred w/CC8   (8) both 8-21wks 2020
Kumar3 body weight Body weight inbred w/CC8   (62) both 8-14wks 2021
Kumar3 open field test Locomotor activity and grooming behavior. inbred w/CC8   (62) both 8-14wks 2021
Kumar4 body size and weight Body length measurements. inbred w/CC8   (62) both 10-20 wks 2021
Kumar4 gait analysis Angular velocity, Stride speed, Step length, Step width, and other gait metrics. inbred w/CC8   (62) both 10-20 wks 2021
Kumar4 open field test Distance traveled. inbred w/CC8   (62) both 10-20 wks 2021
Lesage1 immune cell quantification Immunological cell variation. CC w/par   (76) both 5-8wks 2018
Mathes1 body weight
with exercise 		Baseline vs. after exercise (access to running wheel). CC pre w/par   (184) m 10-12wks 2011
Mathes1 intake monitoring
with exercise 		Caloric intake. Baseline vs. after exercise (access to running wheel). Metabolism, food intake. CC pre w/par   (184) m 10-12wks 2011
Mathes1 monitoring system
with exercise 		Respiratory exchange ratio. Baseline (before access to running wheel). CC pre w/par   (184) m 10-12wks 2011
Mathes1 MRI
with exercise 		Body composition (percent fat). Baseline vs. after exercise (access to running wheel). CC pre w/par   (184) m 10-12wks 2011
Mathes1 running wheel monitoring
with exercise 		Distance, speed at days 1, 6, and 12. CC pre w/par   (184) m 10-12wks 2011
Morgan1 body weight
with high-fat diet and olanzapine 		Body weight and growth curve from age 8wks to 18wks weighed every 2wks. Olanzapine vs. control (both groups high-fat diet). inbred w/CC8   (9) f 8-18wks 2014
Odet2 microscopy Male reproductive sperm motility. inbred w/CC8   (8) m 10-66wks 2015
Powell1 in vitro assay
with Neisseria musculi 		Bacterial load after inoculation with Neisseria musculi. Oral cavity. inbred w/CC8   (8) both 8-16wks 2018
Schughart3 body weight
with influenza A (H3N2) virus 		Influenza A (H3N2) virus (several doses) vs. baseline. Several timepoints. inbred w/CC8   (8) both 7-13wks 2013
Schughart3 health assessment
with influenza A (H3N2) virus 		Survival rate, susceptibility, influenza A (H3N2) virus (several doses). inbred w/CC8   (8) both 7-13wks 2013
Schughart4 body weight
with influenza A (H3N2) virus 		Influenza A (H3N2) virus vs. controls. Several timepoints. inbred w/CC8   (8) f 8-12wks 2016
Schughart4 complete blood count
with influenza A (H3N2) virus 		White blood cell count and differentials. Influenza A (H3N2) virus vs. controls. inbred w/CC8   (8) f 8-12wks 2016
Schughart4 in vitro assay
with influenza A (H3N2) virus 		Viral load in lungs after infection with influenza A (H3N2) virus. inbred w/CC8   (8) f 8-12wks 2016
Schughart5 body weight
with influenza A (H3N2) virus 		Influenza A (H3N2) virus vs. controls. Several timepoints. inbred w/CC8   (8) f 8-12wks 2016
Schughart5 organ weights
with influenza A (H3N2) virus 		Lung weight. Animals infected with influenza A (H3N2) virus vs. controls. inbred w/CC8   (8) f 8-12wks 2016
Shorter3 colony observation Litter size assessment. CC diallel w/par   (62) f 3wks 2018
Sunde1 body weight
with selenium 		Body weight curve 3 to 12 wks, control group. inbred w/CC8   (8) m 3-14wks 2018
Sunde1 RNA expression profiling
with selenium 		Selenium regulation of selenoprotein enzyme activity and transcripts. inbred w/CC8   (8) m 3-14wks 2018
UNC-GMUGA1 genotyping SNP profiling, 130,000+ genomic locations, 1-19,X,Y,MT. CC w/par   (77) m 2020
UNC-MMUGA2 genotyping SNP profiling, 76,000+ genomic locations, 1-19,X,MT CC w/par   (77) both 2017